Morgan Stanley Maintains Overweight on Sana Biotechnology, Raises Price Target to $13
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Maxwell Skor maintains Sana Biotechnology (NASDAQ:SANA) with a Overweight and raises the price target from $12 to $13.
Morgan Stanley analyst Maxwell Skor maintains Sana Biotechnology (NASDAQ:SANA) with a Overweight and raises the price target from $12 to $13.
